Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 12—December 2011


Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies

Pedro PiccardoComments to Author , Larisa Cervenakova, Irina Vasilyeva, Oksana Yakovleva, Igor Bacik, Juraj Cervenak, Carroll McKenzie, Lubica Kurillova, Luisa Gregori, Kitty Pomeroy, and David M. Asher
Author affiliations: University of Edinburgh, Easter Bush, UK, (P. Piccardo); Food and Drug Administration, Kensington, Maryland, USA (P. Piccardo, I. Bacik, J. Cervenak, L. Kurillova, L. Gregori, K. Pomeroy, D.M. Asher); Holland Laboratory American Red Cross, Rockville, Maryland, USA (L. Cervenakova, I. Vasilyeva, O. Yakovleva, C. McKenzie)

Main Article

Table 2

Cell lines exposed to BSE or vCJD or normal bovine or human brain suspension and bioassayed in TgBo mice*

CHO 21 9 720 17 9 730
Vero 20 10 730 ND ND ND
WI-38 23 10 730 ND ND ND
R9ab 18 9 630 ND ND ND
MDCK 19 10 730 20 10 730
HEK-293 20 20 730 ND ND ND
Mo3F4-3T3 17 10 750 ND ND ND

*BSE, bovine spongiform encephalopathy; vCJD, variant Creutzfeldt-Jakob disease; NB, normal brain; dpi, days postinculation at cull; ND, not done; CHO, Chinese hamster ovary; Vero, African green monkey kidney; WI-38, human lung diploid fibroblasts; R9ab, rabbit fibroblasts; MDCK, dog kidney; HEK-293, human embryonic kidney; Mo3F4-3T3, mouse fibroblasts.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO